PLA2G10

Chr 16

phospholipase A2 group X

Also known as: GXPLA2, GXSPLA2, SPLA2, sPLA2-X

NCBI Gene: 8399ENSG00000069764UniProt: O15496

This gene encodes a member of the phospholipase A2 family of proteins. Alternative splicing results in multiple transcript variants, at least one of which encodes a preproprotein that is proteolytically processed to generate the mature enzyme. This calcium-dependent enzyme hydrolyzes glycerophospholipids to produce free fatty acids and lysophospholipids. In one example, this enzyme catalyzes the release of arachidonic acid from cell membrane phospholipids, thus playing a role in the production of various inflammatory lipid mediators, such as prostaglandins. The encoded protein may promote the survival of breast cancer cells through its role in lipid metabolism. [provided by RefSeq, Nov 2015]

49
ClinVar variants
25
Pathogenic / LP
0.07
pLI score
1
Active trials
Clinical Summary— PLA2G10
⚡
Population Constraint (gnomAD)
Low constraint (pLI 0.07) — loss-of-function variants are relatively tolerated in the population.
📋
ClinVar Variants
25 Pathogenic / Likely Pathogenic· 20 VUS of 49 total submissions
💊
Clinical Trials
1 active or recruiting trial — potential therapeutic options may be available

Population Genetics & Constraint

gnomAD v4 — loss-of-function & missense intolerance

gnomAD
Tolerant — LoF & missense variants common in population
LoF Constraint?LOEUF (Loss-of-function Observed/Expected Upper bound Fraction) is the upper bound of the 90% CI for LoF OE — the preferred gnomAD v4 metric. Lower = more intolerant to LoF. LOEUF < 0.35 = highly constrained.
1.93LOEUF
pLI 0.070
Z-score -0.68
OE 2.05 (0.34–1.93)
Tolerant

Highly tolerant — LoF variants common in population

Missense Constraint?Missense Z-score: standard deviations fewer missense variants observed vs. expected. Z > 3.09 (p < 0.001) = gene does not tolerate missense variation. OE missense < 0.6 is also considered constrained.
-0.03Z-score
OE missense 1.02 (0.74–1.42)
25 obs / 24.6 exp
Tolerant

Tolerant to missense variation

Observed / Expected Ratios?Shaded band = 90% confidence interval. Vertical tick = point estimate. Grey threshold line = gnomAD constraint cutoff for that variant class.
LoF OE?Ratio of observed to expected LoF variants. Upper CI bound (LOEUF) ≤ 0.35 = strong LoF constraint signal.2.05 (0.34–1.93)
0≤0.351.4
Missense OE?Ratio of observed to expected missense variants. OE ≤ 0.6 = fewer missense variants than expected by chance.1.02 (0.74–1.42)
0≤0.61.4
Synonymous OE?Control metric — synonymous variants are largely neutral and expected near OE = 1.0. Significant deviation may indicate annotation issues.0.76
0≤1.21.6
LoF obs/exp: 1 / 0.5Missense obs/exp: 25 / 24.6Syn Z: 0.66

ClinVar Variant Classifications

49 submitted variants in ClinVar

ClinVar

Classification Summary

Pathogenic20
Likely Pathogenic5
VUS20
Likely Benign3
20
Pathogenic
5
Likely Pathogenic
20
VUS
3
Likely Benign

Curated Variants Distribution

Classified variants from ClinVar · 5 ACMG categories

ClassificationLoFMissense + InframeNon-codingSynonymousTotal
Pathogenic
0
0
20
0
20
Likely Pathogenic
0
0
5
0
5
VUS
0
7
13
0
20
Likely Benign
0
1
1
1
3
Benign
0
0
0
0
0
Total0839148

LoF = frameshift, stop gained/lost, canonical splice · Counts from ClinVar esearch · Updated hourly

View in ClinVar →

Protein Context — Lollipop Plot

PLA2G10 · protein map & ClinVar variants

Showing all ClinVar variants across the protein. Search a specific variant to highlight its position.

OMIM — Genotype-Phenotype Relationships

1 OMIM entry

OMIM
Clinical Literature
Landmark / reviewRecent case evidence
Key Publications
Landmark & review papers · by relevance
PubMed
PLA2G10 incorporated in exosomes could be diagnostic and prognostic biomarker for non-small cell lung cancer.
Chen Y et al.·Clin Chim Acta
2022
Tumor PLA2G10 restrains CD4(+) T cell activation in lung adenocarcinoma via enhancing arachidonic acid secretion.
Tian Y et al.·Int J Biol Macromol
2025
PLA2G10 Gene Variants, sPLA2 Activity, and Coronary Heart Disease Risk.
Guardiola M et al.·Circ Cardiovasc Genet
2015Clinical trial
Group X secreted phospholipase A2 limits the development of atherosclerosis in LDL receptor-null mice.
Ait-Oufella H et al.·Arterioscler Thromb Vasc Biol
2013
Construction and validation of a metabolism-related prognostic model for thyroid cancer.
Li P et al.·Am J Otolaryngol
2023Functional
Network pharmacology and metabolomics elucidate the underlying effects and mechanisms of maackiain against endometrial cancer.
Xing Y et al.·Biochem Biophys Res Commun
2025Functional
Top 10 resultsSearch PubMed ↗
Recent Gene-Specific Literature
Gene in title · MEDLINE · newest first
Europe PMC
Top 5 resultsSearch Europe PMC ↗

Clinical Trials

Active and recruiting trials from ClinicalTrials.gov

ClinicalTrials.gov
COVID-19

Arginine Replacement Therapy in COVID-19

RECRUITING
NCT05855330Phase PHASE2Emory UniversityStarted 2024-01-08
Arginine Hydrochloride

External Resources

Links to major genomics databases and tools